StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)

Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –

Halozyme Therapeutics, Inc. grew revenue 41.2% to $1.66B over the twelve months to Jun 30, 2026. Operating income fell 12.5% to $597.20M, moving the operating margin from 57.9% to 35.9%. Free cash flow was $806.22M, up 49.1% from a year earlier. At the latest close the market valued the company at $10.89B, 28.3 times its earnings.

Revenue
$1.66B
+41.2% vs. a year earlier
Operating income
$597.20M
-12.5% vs. a year earlier
Free cash flow
$806.22M
+49.1% vs. a year earlier
EPS, diluted
$3.39
-22.4% vs. a year earlier

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$10.89B
P/E ratio
28.3
Price to sales
6.55
Price to book
75.88
Dividend yield
–
Free cash flow yield
7.40%

Fundamentals

Revenue
$1.66B
Net income
$413.60M
EPS, diluted
$3.39
Free cash flow
$806.22M
Book value per share
$1.18
Diluted shares
121M

Trading

Next earnings
Feb 16, 2027 (estimated, after the close)
Previous close
$96.50
Open
$95.99
Day's range
$94.93 – $97.01
Volume
2,041,121
Average volume (20 days)
2,366,894
Index membership
S&P MidCap 400 (since Nov 2020), Russell 1000 (since Jun 2025), Russell 3000
52-week range
$61.23 – $134.00
RSI (14 days)
23.8
Volatility (1 year)
41.1%
Relative volume
0.94×

On 1 of our idea list: Buyback cannibals

Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodHALOS&P 500DifferenceHALO per yearS&P 500 per year
1 month-21.2%-4.0%−17.2 pts
3 months-6.8%-5.0%−1.9 pts
Year to date+42.6%+8.2%+34.4 pts
1 year+36.0%+11.2%+24.8 pts
3 years+140.3%+68.5%+71.9 pts+34.0%+19.0%
5 years+160.6%+67.3%+93.4 pts+21.1%+10.8%
10 years+639.4%+291.6%+347.7 pts+22.1%+14.6%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$1.66B+41.2% YoY

Gross profit

$1.37B+38.2% YoY

Operating income

$597.20M-12.5% YoY

Net income

$413.60M-25.8% YoY

EPS, diluted

$3.39-22.4% YoY

Free cash flow

$806.22M+49.1% YoY
Reported periodTrailing twelve months

Press releases

Releases Halozyme Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Halozyme Therapeutics

Biological Products, (No Diagnostic Substances)

Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes drug delivery platforms and specialized injection devices. The company's core offering is its ENHANZE technology, powered by the proprietary recombinant human hyaluronidase enzyme rHuPH20, which facilitates rapid subcutaneous delivery of injectable biologics and fluids to reduce patient treatment burden. Halozyme also develops the Hypercon and Surf Bio drug concentration technologies, alongside pressure-assisted auto-injectors and multi-dose pens. Its business model spans licensing proprietary delivery platforms to biopharmaceutical partners, collaborative drug-device product development, and the direct commercialization of proprietary offerings such as Hylenex recombinant and XYOSTED. Customers and collaborators include major global pharmaceutical companies, healthcare providers, and patients.

Company profile, executives and history

Halozyme Therapeutics stock: common questions

What is Halozyme Therapeutics's stock price?

HALO closed at $95.97 on Nov 17, 2026, down 0.55% on the day. Over the past 52 weeks it traded between $61.23 and $134.00.

What is Halozyme Therapeutics's market cap?

Halozyme Therapeutics was worth $10.89B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is HALO's P/E ratio?

HALO trades at 28.3 times earnings, based on diluted earnings per share of $3.39 over the twelve months to Jun 30, 2026.

How much revenue does Halozyme Therapeutics make?

Halozyme Therapeutics reported revenue of $1.66B for the twelve months to Jun 30, 2026, up 41.2% from a year earlier.

Does Halozyme Therapeutics pay a dividend?

No. Halozyme Therapeutics has not paid a cash dividend over the last twelve months.

When does Halozyme Therapeutics report earnings next?

Halozyme Therapeutics is expected to report Q4 FY2026 results on Feb 16, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has HALO stock performed over the past year?

Including dividends, HALO returned +36.0% over the past year, against +11.2% for the S&P 500.

How many HALO shares are sold short?

14M shares were sold short at the latest FINRA report, 12.18% of the float, or 6.8 days of average trading volume.

Who are Halozyme Therapeutics's competitors?

Companies most similar to Halozyme Therapeutics by business, industry and size include BCRX, BNTX, NBIX, MRNA, RGEN.

See a number that looks wrong?